Scroll
To Top

Archives for: May 10th, 2017

NORD Issues Statement on Confirmation of New FDA Commissioner, Dr. Scott Gottlieb

Written by Christina Jensen on May 10, 2017

Washington, D.C., May 10, 2017—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement on the confirmation by the U.S. Senate of Scott Gottlieb, M.D., as Commissioner of the Food and Drug Administration (FDA):

“We at the National Organization for… Read More

Advocacy Alert: Tell Congress to Act Now and Pass FDA User Fee Agreements

Written by Jennifer Huron on April 5, 2017

Lawmakers are currently considering legislation to reauthorize FDA user fees. The FDA largely relies on user fees to operate and review innovative drugs, biologics, and devices.  Not only does this legislation provide critical funding for FDA to quickly review products, but the user fee agreements also provide patients and… Read More

NORD Issues Statement on President Trump’s Address to Congress

Written by Jennifer Huron on March 1, 2017

NORD Issues Statement on President Trump’s Address to Congress

Washington, D.C., March 1, 2017—The National Organization for Rare Disorders (NORD), the leading independent nonprofit organization representing the 30 million Americans with rare diseases, issued the following statement in response to President Trump’s first speech to Congress:

“Yesterday evening, President Trump… Read More